Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Francisco Carabantes Ocón"'
Autor:
Julia Alcalde García, Francisco Carabantes Ocón, Inmaculada Alés Díaz, Manuel Benavides Orgaz, Vanesa Gutiérrez Calderón, Silvia Gil Calle, Esther Villar Chamorro, Alvaro Montesa Pino, Juan José Bretón García, Manuel Cobo Dols
Publikováno v:
Clinicaltranslational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 8(10)
Objective. We conducted this phase II trial to evaluate the efficacy and toxicity of the sequential nonplatinum combination chemotherapy consisting of gemcitabine (GEM) and vinorelbine (VNR) followed by weekly docetaxel (DOC) in patients with advance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd6308a0c704fdab08166f04f633785c
https://pubmed.ncbi.nlm.nih.gov/17074673
https://pubmed.ncbi.nlm.nih.gov/17074673
Autor:
Esther Villar-Chamorro, Vanesa Gutiérrez-Calderón, Juan J. Bretón-García, Álvaro Montesa-Pino, Inmaculada Alés-Díaz, Manuel Cobo-Dols, Manuel Benavides-Orgaz, Silvia Gil-Calle, Julia Alcalde-García, Francisco Carabantes-Ocón
Publikováno v:
Clinicaltranslational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 8(7)
In this Phase I/II trial, the maximumtolerated dose (MTD) and activity of cisplatin plus vinorelbine (VRL) administered in continuous infusion as first-line treatment of advanced non small cell lung cancer (NSCLC) was determined in 12 consecutive che
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd7438e8572d63f36b9e0c3f7337fb7a
https://pubmed.ncbi.nlm.nih.gov/16870542
https://pubmed.ncbi.nlm.nih.gov/16870542